Statement of Changes in Beneficial Ownership (4)
December 19 2019 - 4:39PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Leveque Joseph |
2. Issuer Name and Ticker or Trading Symbol
Synthorx, Inc.
[
THOR
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Medical Officer |
(Last)
(First)
(Middle)
C/O SYNTHORX, INC., 11099 N. TORREY PINES ROAD, SUITE 190 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
12/17/2019 |
(Street)
LA JOLLA, CA 92037
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 12/17/2019 | | A | | 20000 (1) | A | $0.00 | 283910 (2) | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Explanation of Responses: |
(1) | Represents restricted stock unit award granted under the Issuer's 2018 Equity Incentive Plan. |
(2) | Includes 2,883 shares of Common Stock that were acquired by the Reporting Person on June 14, 2019 pursuant to the Issuer's Employee Stock Purchase Plan and 1,662 shares of Common Stock that were acquired by the Reporting Person on December 13, 2019 pursuant to the Issuer's Employee Stock Purchase Plan. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Leveque Joseph C/O SYNTHORX, INC. 11099 N. TORREY PINES ROAD, SUITE 190 LA JOLLA, CA 92037 |
|
| Chief Medical Officer |
|
Signatures
|
/s/ Christian V. Kulen, Attorney-in-Fact | | 12/19/2019 |
**Signature of Reporting Person | Date |
Synthorx (NASDAQ:THOR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Synthorx (NASDAQ:THOR)
Historical Stock Chart
From Sep 2023 to Sep 2024